Shu-Shu Li on Muck Rack

Shu-Shu Li

As seen in: Frontiers, BMC Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shu-Shu

Contact Shu-Shu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Xingpi Yanger Granule combined with conventional medication for the treatment of nocturnal enuresis: a systematic review and meta-analysis of randomized controlled trials

|
By Tao Lin Sun, Shu-Shu Li, Hong Zheng, Ru-Ping Zhao, Qiu-Wen Zhang, Mu-Yuan Guo
| Frontiers
Abstract Objective: This systematic review aims to determine the clinical efficacy and safety of Xingpi Yanger Granule (XPYEG) in combination with conventional medication for the treatment of Nocturnal Enuresis based on existing data.
Open in Who Shared Issue with article?

Prognostic nutritional index predicts survival in intermediate and advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with PD-(L)1 inhibitors and molecular targeted therapies | BMC Cancer | Full Text

|
By Hao-Huan Tang, Ming-Qing Zhang, Zi-Chen Zhang, Chen Fan, Wei Chen, Wei-Dong Wang, Shu-Shu Li
| BMC Cancer Verified
A retrospective analysis was conducted on HCC patients who consecutively received the triple therapy (HAIC + PD-(L) 1 inhibitors + MTTs) from January 2020 to August 2022 in three affiliated hospitals of universities (tertiary medical institutions) (Fig. 1).
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified